Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 2898-2908

  Hu, Leijun ^a   Hansen, Ryan J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Allometry; Antibody; Computational biology; Nonlinear pharmacokinetics; Pharmacodynamics; Pharmacokinetics; Pharmacokinetics pharmacodynamics; Physiological model; PK PD

Indexed keywords

BISPECIFIC ANTIBODY; CD4 ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; METHOTREXATE; MONOCLONAL ANTIBODY;

ALLOMETRY; ANIMAL MODEL; ANTIBODY ENGINEERING; ARTICLE; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG STRUCTURE; DRUG TARGETING; HUMAN VERSUS ANIMAL COMPARISON; MATHEMATICAL MODEL; MOLECULAR MODEL; NONHUMAN; PHARMACODYNAMICS; PREDICTION; PROCESS DESIGN; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; SIMULATION; SYSTEMIC CIRCULATION; TRANSLATIONAL RESEARCH;

ALLOMETRY; ANTIBODY; COMPUTATIONAL BIOLOGY; NONLINEAR PHARMACOKINETICS; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOKINETICS/PHARMACODYNAMICS; PHYSIOLOGICAL MODEL; PK/PD;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL;

EID: 84881616388     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23504     Document Type: Article

References (88)

1. Society TA. Therapeutic monoclonal antibodies approved or in review in the European Union or United States as of June, 2012. Accessed, at: 03-06-2013. http://www.antibodysociety.org.
2. Deng R, Jin F, Prabhu S, Iyer S. 2012. Monoclonal antibodies: What are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 8(2):141-160.
3. Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW. 2012. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem 3(4):73-92.
4. Wang W, Wang EQ, Balthasar JP. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84(5):548-558.
5. Lobo ED, Hansen RJ, Balthasar JP. 2004. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93(11):2645-2668.
6. Boswell CA, Bumbaca D, Fielder PJ, Khawli LA. 2012. Compartmental tissue distribution of antibody therapeutics: Experimental approaches and interpretations. AAPS J 14(3):612-618.
7. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. 2010. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21(12):2153-2163.
8. Bumbaca D, Boswell CA, Fielder PJ, Khawli LA. 2012. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J 14(3):554-558.
9. McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA. 2010. Subcutaneous administration of biotherapeutics: Current experience in animal models. Curr Opin Mol Ther 12(4):461-470.
10. Richter WF, Bhansali SG, Morris ME. 2012. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J 14(3):559-570.
11. Tabrizi M, Funelas C, Suria H. 2010. Application of quantitative pharmacology in development of therapeutic monoclonal antibodies. AAPS J 12(4):592-601.
12. Zhao L, Shang EY, Sahajwalla CG. 2012. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development. J Pharm Sci 101(12):4367-4382.
13. Hansen RJ, Balthasar JP. 2003. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 92(6):1206-1215.
14. Deng R, Balthasar JP. 2007. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. J Pharm Sci 96(6):1625-1637.
15. Lon HK, Liu D, Zhang Q, DuBois DC, Almon RR, Jusko WJ. 2011. Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis. Pharm Res 28(7):1622-1630.
16. Schlessinger L, Eddy DM. 2002. Archimedes: A new model for simulating health care systems-The mathematical formulation. J Biomed Inform 35(1):37-50.
17. Peterson MC, Riggs MM. 2010. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 46(1):49-63.
18. Riggs MM, Peterson MC, Gastonguay MR. 2012. Multiscale physiology-based modeling of mineral bone disorder in patients with impaired kidney function. J Clin Pharmacol 52(1 Suppl):45S-53S.
19. Grossman HL, Schlender A, Alperin P, Stanley EL, Zhang J. 2010. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma. Curr Med Res Opin 26(12):2779-2793.
20. Eddy DM, Schlessinger L. 2003. Archimedes: A trial-validated model of diabetes. Diabetes Care 26(11):3093-3101.
21. Green LE, Dinh TA, Smith RA. 2012. An estrogen model: The relationship between body mass index, menopausal status, estrogen replacement therapy, and breast cancer risk. Comput Math Methods Med 2012:792375.
22. Eddy DM, Schlessinger L, Heikes K. 2008. The metabolic syndrome and cardiovascular risk: Implications for clinical practice. Int J Obes (Lond) 32 Suppl 2:S5-S10.
23. Kahn R, Robertson RM, Smith R, Eddy D. 2008. The impact of prevention on reducing the burden of cardiovascular disease. Circulation 118(5):576-585.
24. Harrold JM, Straubinger RM, Mager DE. 2012. Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Res 72(7):1632-1641.
25. Mager DE, Jusko WJ. 2001. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28(6):507-532.
26. Mager DE, Krzyzanski W. 2005. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22(10):1589-1596.
27. Gibiansky L, Gibiansky E, Kakkar T, Ma P. 2008. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35(5):573-591.
28. Gibiansky L, Gibiansky E. 2010. Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 37(4):323-346.
29. Friedrich S. 2007. Characterizing nonlinear pharmacokinetics: An example scenario for a therapeutic protein. In Pharmacometrics: The science of quantitative pharmacology; Ette E, Williams P, Eds. New Jersey: John Wiley and Sons, pp 1137-1156.
30. Aston PJ, Derks G, Raji A, Agoram BM, van der Graaf PH. 2011. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: Predicting in vivo potency. J Theor Biol 281(1):113-121.
31. Davda JP, Hansen RJ. 2010. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs 2(5):576-588.
32. Xin Y, Xiang H, Jin D, Theil FP, Joshi A, Damico-Beyer LA, Bai S. 2012. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model. J Pharmacokinet Pharmacodyn 39(2):217-226.
33. Xiao JJ, Krzyzanski W, Wang YM, Li H, Rose MJ, Ma M, Wu Y, Hinkle B, Perez-Ruixo JJ. 2010. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J 12(4):646-657.
34. Garg A, Balthasar JP. 2007. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34(5):687-709.
35. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. 1986. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 46(8):3969-3978.
36. Baxter LT, Zhu H, Mackensen DG, Jain RK. 1994. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54(6):1517-1528.
37. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. 1995. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 55(20):4611-4622.
38. Zhu H, Jain RK, Baxter LT. 1998. Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med 39(1):65-76.
39. Friedrich SW, Lin SC, Stoll BR, Baxter LT, Munn LL, Jain RK. 2002. Antibody-directed effector cell therapy of tumors: Analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia 4(5):449-463.
40. Ferl GZ, Wu AM, 3rd DiStefano JJ. 2005. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 33(11):1640-1652.
41. Fang L, Sun D. 2008. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy. Drug Metab Dispos 36(6):1153-1165.
42. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH. 2008. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8(3):401-413.
43. Kletting P, Bunjes D, Reske SN, Glatting G. 2009. Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model. J Nucl Med 50(2):296-302.
44. Urva SR, Yang VC, Balthasar JP. 2010. Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody. J Pharm Sci 99(3):1582-1600.
45. Chabot JR, Dettling DE, Jasper PJ, Gomes BC. 2011. Comprehensive mechanism-based antibody pharmacokinetic modeling. Conf Proc IEEE Eng Med Biol Soc 2011:4318-4323.
46. Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, Fielder PJ, Khawli LA. 2011. Effects of anti-VEGF on predicted antibody biodistribution: Roles of vascular volume, interstitial volume, and blood flow. PLoS One 6(3):e17874.
47. Rhoden JJ, Wittrup KD. 2012. Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J Pharm Sci 101(2):860-867.
48. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. 2012. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503:255-268.
49. Shah DK, Betts AM. 2012. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67-86.
50. Dayneka NL, Garg V, Jusko WJ. 1993. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21(4):457-478.
51. Sharma A, Davis CB, Tobia LA, Kwok DC, Tucci MG, Gore ER, Herzyk DJ, Hart TK. 2000. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther 293(1):33-41.
52. Lobo ED, Soda DM, Balthasar JP. 2003. Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice. J Pharm Sci 92(8):1665-1676.
53. Yu J, Karcher H, Feire AL, Lowe PJ. 2011. From target selection to the minimum acceptable biological effect level for human study: Use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J 13(2):169-178.
54. Jumbe NL, Xin Y, Leipold DD, Crocker L, Dugger D, Mai E, Sliwkowski MX, Fielder PJ, Tibbitts J. 2010. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. J Pharmacokinet Pharmacodyn 37(3):221-242.
55. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018-1028.
56. Agency EM. 2007. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. http://www.emea.europa.eu.
57. Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. 2009. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol 20(6):722-729.
58. Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, Abdiche Y, Stone DM, Paralkar VM. 2010. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 333(1):2-13.
59. Ling J, Zhou H, Jiao Q, Davis HM. 2009. Interspecies scaling of therapeutic monoclonal antibodies: Initial look. J Clin Pharmacol 49(12):1382-1402.
60. Mahmood I. 2009. Pharmacokinetic allometric scaling of antibodies: Application to the first-in-human dose estimation. J Pharm Sci 98(10):3850-3861.
61. Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA. 2011. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: Retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 50(2):131-142.
62. Oitate M, Masubuchi N, Ito T, Yabe Y, Karibe T, Aoki T, Murayama N, Kurihara A, Okudaira N, Izumi T. 2011. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet 26(4):423-430.
63. Han C, Zhou H. 2011. Monoclonal antibodies: Interspecies scaling with minimal preclinical information. Ther Deliv 2(3):359-368.
64. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. 2011. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? MAbs 3(1):61-66.
65. Oitate M, Nakayama S, Ito T, Kurihara A, Okudaira N, Izumi T. 2012. Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by a species-invariant time method. Drug Metab Pharmacokinet 27(3):354-359.
66. Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J. 2010. On setting the first dose in man: Quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 106(3):195-209.
67. Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E. 2012. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 341(3):702-708.
68. Odom-Maryon TL, Williams LE, Chai A, Lopatin G, Liu A, Wong YC, Chou J, Clarke KG, Raubitschek AA. 1997. Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans. J Nucl Med 38(12):1959-1966.
69. Meissner HC, Groothuis JR, Rodriguez WJ, Welliver RC, Hogg G, Gray PH, Loh R, Simoes EA, Sly P, Miller AK, Nichols AI, Jorkasky DK, Everitt DE, Thompson KA. 1999. Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease. Antimicrob Agents Chemother 43(5):1183-1188.
70. Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS, Rohane P, Staehelin T, van Steijn AM, Frank W. 1997. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther 62(6):675-690.
71. Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, Totoritis MC. 1999. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin Pharmacol Ther 66(3):246-257.
72. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. 1999. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27(4):397-420.
73. Bai S, Jorga K, Xin Y, Jin D, Zheng Y, Damico-Beyer LA, Gupta M, Tang M, Allison DE, Lu D, Zhang Y, Joshi A, Dresser MJ. 2012. A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet 51(2):119-135.
74. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. 2009. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 49(9):1012-1024.
75. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. 2005. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res 22(9):1432-1437.
76. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD. 2012. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17(9-10):419-424.
77. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J. 2006. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 98(9):580-598.
78. Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, Deniz Y, Lowman H, Fielder P, Visich J, Joshi A, Jumbe NS. 2008. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J 10(2):425-430.
79. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. 2009. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 68(1):61-76.
80. Tang C, Prueksaritanont T. 2011. Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: Temporal profiles of 'free' and 'total' drug and target. Pharm Res 28(10):2447-2457.
81. Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, Chow AT, Perez-Ruixo JJ. 2011. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 50(12):793-807.
82. Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ. 2005. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22(7):1088-1100.
83. Grimm HP. 2009. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn 36(5):407-420.
84. Kletting P, Kull T, Bunjes D, Luster M, Reske SN, Glatting G. 2011. Optimal preloading in radioimmunotherapy with anti-cD45 antibody. Med Phys 38(5):2572-2578.
85. Kletting P, Kull T, Bunjes D, Mahren B, Luster M, Reske SN, Glatting G. 2010. Radioimmunotherapy with anti-CD66 antibody: Improving the biodistribution using a physiologically based pharmacokinetic model. J Nucl Med 51(3):484-491.
86. Kletting P, Meyer C, Reske SN, Glatting G. 2010. Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: An investigation based on pharmacokinetic modeling. Cancer Biother Radiopharm 25(3):279-287.
87. Nesterov I. 2007. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 3(2):235-249.
88. Marathe DD, Marathe A, Mager DE. 2011. Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharm Drug Dispos 32(8):471-481.